Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Restoring microglial lysosomal capacity in neurodegeneration

Objective

Alzheimer’s disease (AD) is the most common cause of dementia, affecting over 57 million people worldwide. It is a progressive, fatal neurodegenerative disorder with no curative treatments, imposing a major burden on patients, families, healthcare systems, and society.
AD is marked by amyloid-beta (Aβ) plaque accumulation. Microglia, the brain’s immune cells, attempt to degrade these aggregates through their lysosomes, but this process is often inefficient and may even contribute to Aβ spread.
I hypothesize that Aβ pathology reshapes the proteome of human microglial lysosomes, impairing their function and promoting disease progression. To date, no study has systematically mapped how the human microglial lysosomal proteome changes dynamically in response to Aβ pathology.
To address this knowledge gap, I will use a xenotransplantation model in which human iPSC-derived microglia are engrafted into either healthy or Aβ-accumulating mouse brains. TurboID proximity labeling will enable in vivo profiling of lysosomal proteins altered by Aβ pathology. To test the functional consequences of this alteration, I will employ a targeted CRISPR/Cas9 screen in human microglia-neuron-astrocyte tri-cultures, identifying genes whose disruption enhances Aβ clearance. Promising candidates will be then validated in vivo using antisense oligonucleotides.
The host laboratory has established the xenotransplantation model, the TurboID system, and the CRISPR platform, while I bring extensive expertise in human tri-cultures. I therefore believe that this makes an unprecedented opportunity to move beyond the state of the art and address a major gap in AD research.
The project will generate the first in vivo map of the human microglial lysosomal proteome under Aβ pathology, uncovering candidate therapeutic targets to restore clearance. In doing so, it will open new avenues to modify AD and other neurodegenerative disorders where protein accumulation and microglia dysfunction are key drivers.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

VIB VZW
Net EU contribution
€ 216 240,00
Address
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgium
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Research Organisations
Links
Total cost
No data